Barclays PLC Has $2.21 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT)
Barclays PLC Has $2.21 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT)
Barclays PLC raised its stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Get Rating) by 5,227.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 148,256 shares of the technology company's stock after purchasing an additional 145,473 shares during the period. Barclays PLC owned 0.32% of Cogent Biosciences worth $2,211,000 as of its most recent SEC filing.
根據該公司最近向證券交易委員會提交的 13F 表格中，巴克萊集團在第三季度將其在科金特生物科學公司（NASDAQ：COGT-獲得評級）的股份股份增加了 5,227.2％ 的股份。該基金在期內額外購買 145,473 股股票後，擁有該科技公司股票的 148,256 股股份。截至最近的 SEC 申請，巴克萊有限公司擁有令人信服生物科學的 0.32％，價值 2,211,000 美元。
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its holdings in Cogent Biosciences by 43.5% during the third quarter. SG Americas Securities LLC now owns 24,467 shares of the technology company's stock valued at $365,000 after purchasing an additional 7,418 shares during the last quarter. Deerfield Management Company L.P. Series C boosted its position in shares of Cogent Biosciences by 267.1% in the second quarter. Deerfield Management Company L.P. Series C now owns 5,876,805 shares of the technology company's stock valued at $53,009,000 after acquiring an additional 4,275,805 shares during the period. Amalgamated Bank bought a new stake in shares of Cogent Biosciences in the first quarter valued at approximately $37,000. Pura Vida Investments LLC bought a new stake in shares of Cogent Biosciences in the second quarter valued at approximately $2,154,000. Finally, Tekla Capital Management LLC bought a new stake in shares of Cogent Biosciences in the second quarter valued at approximately $1,325,000.
其他對沖基金和其他機構投資者最近也增加或減少了他們在公司的股份。新加坡美洲證券有限責任公司在第三季度增長了 43.5％ 在科特生物科學的持有量。新加坡美洲證券有限責任公司在上一季度額外購買 7,418 股股票後，現在擁有該科技公司股票價值 365,000 美元的 24,467 股股票。迪爾菲爾德管理公司 L.P 系列 C 在第二季度提高了其在科特生物科學股份的地位 267.1％。迪爾菲管理公司 L.P 系列 C 系列現在擁有該科技公司 5,876,805 股股份，價值為 53,009,000 美元，在期內額外收購 4,275,805 股股份。合併銀行在第一季度購買了科金特生物科技股份的新股份，價值約為 37,000 美元。普拉維達投資有限責任公司在第二季度購買了科金特生物科技股份的新股份，價值約為 2,154,000 美元。最後，Tekla 資本管理有限責任公司在第二季度購買了科金特生物科技股份的新股份，價值約為 1,325,000 美元。
Wall Street Analysts Forecast Growth
華爾街分析師預測增長
Several equities research analysts have recently weighed in on COGT shares. Guggenheim increased their price objective on Cogent Biosciences from $22.00 to $24.00 and gave the company a "buy" rating in a research report on Tuesday, December 13th. Wedbush reduced their price objective on Cogent Biosciences to $19.00 in a research report on Wednesday, November 16th. SVB Leerink increased their price objective on Cogent Biosciences from $18.00 to $20.00 and gave the company an "outperform" rating in a research report on Thursday, January 5th. Finally, Needham & Company LLC began coverage on Cogent Biosciences in a research report on Wednesday, December 14th. They issued a "buy" rating and a $24.00 price objective for the company.
幾位股票研究分析師最近對 COGT 股票進行了權衡。古根海姆提高了他們對科根生物科學的價格目標從 $22.00 到 $24.00 並給了該公司一個「買」評級在週二的研究報告, 12 月 13 日.韋布什降低其價格目標對科金特生物科學 $19.00 在研究報告上週三, 11 月 16 日.SVB Leerink 提高了他們對可信生物科學的價格目標從 18.00 美元至 $20.00，並在 1 月 5 日星期四的一份研究報告中給予該公司「跑贏大市」評級。最後, 李約翰 & 公司有限責任公司開始覆蓋科金特生物科學在研究報告上週三, 12 月 14 日.他們為該公司發布了「買入」評級和 24.00 美元的價格目標。
Cogent Biosciences Price Performance
信譽生物科學價格表現
Cogent Biosciences (NASDAQ:COGT – Get Rating) last issued its earnings results on Monday, November 14th. The technology company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.01. Equities research analysts anticipate that Cogent Biosciences, Inc. will post -2.31 EPS for the current year.
信譽生物科學（NASDAQ：COGT-獲得評級）上次公佈了 11 月 14 日（週一）的盈利業績。該科技公司報告了本季每股收益（0.50 美元），超過 0.51 美元的共識估計（0.51 美元）。股票研究分析師預計，科金特生物科技股份有限公司將在本年度公佈 -2.31 每股盈餘。
Cogent Biosciences Profile
信任生物科學概況
(Get Rating)
(取得評分)
Cogent Biosciences, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17.
Cogent Biosciences, Inc 是一家臨床階段的生物製藥公司，致力於基因定義疾病的精準療法的開發和商業化。它專注於 CGT9486，一種選擇性酪氨酸激酶抑製劑，旨在有效抑制 KIT D816V 突變以及 KIT 外顯子 17 中的其他突變。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Cogent Biosciences (COGT)
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
- Mullen Automotive Stock Gains Momentum On Positive News
- Harley-Davidson Inc. Stock, Is It Time To Buy?
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air's Recent Earnings
- 免費獲取有關科金生物科學研究報告的副本
- 凱西·伍茲的方舟創新 ETF 將在 2023 年反彈？
- 馬倫汽車股票在積極新聞中獲得動力
- 哈雷戴維森公司股票，是時候購買了嗎？
- 對於元平台來說，波動性還沒有結束
- 分析阿拉斯加航空的近期盈利
Want to see what other hedge funds are holding COGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cogent Biosciences, Inc. (NASDAQ:COGT – Get Rating).
想看看還有哪些對沖基金持有 COGT？ 訪問 Holdingschannel.com 以獲取信譽生物科技股份有限公司（NASDAQ：COGT — 獲得評分）的最新 13 樓文件和內幕交易。
Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收有關信譽生物科學日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Cogent 生物科學和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。